Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ST14

ST14

Basics

Aliases:
This biomarker is also known as:
  • suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin),
  • EC 3.4.21.109,
  • suppressor of tumorigenicity 14 protein,
  • OTTHUMP00000230932,
  • MTSP1,
  • Prostamin,
  • Serine protease 14,
  • Serine protease TADG-15,
  • EC 3.4.21,
  • suppression of tumorigenicity 14 (colon carcinoma),
  • PRSS14,
  • Membrane-type serine protease 1,
  • OTTHUMP00000230931,
  • Matriptase,
  • TMPRSS14,
  • tumor associated differentially expressed gene 15 protein,
  • TADG15,
  • SNC19,
  • Tumor-associated differentially-expressed gene 15 protein,
  • MT-SP1,
  • prostamin,
  • HAI,
  • Q9Y5Y6,

View in BioMuta

Description…

ST14 protein is an epithelial-derived, integral membrane serine protease and is found to be activated by sphingosine 1-phosphate. The expression of this protease has been associated with breast, colon, prostate, and ovarian tumors, which implicates its role in cancer invasion, and metastasis.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: ST14

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

ST14 localized to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

ST14 was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of ST14 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.